News | ECG | September 29, 2022

HeartBeam Granted Patent for Signal Transformation from Vector Electrocardiogram (VECG) to 12-Lead Electrocardiogram (ECG)

Patented Technology Allows HeartBeam AIMIGo Credit Card-sized Device to Enable a 12-lead ECG Anytime, Anywhere 


September 29, 2022 —  HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere, announced that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo credit card-sized device was issued by the United States Patent and Trademark Office. The innovation opens the pathway for a patient to record a set of signals using HeartBeam AIMIGo outside of a medical setting with a diagnostic synthesized 12-lead ECG immediately transmitted to a physician for review and diagnosis. Unlike single-lead ECG products currently in the marketplace, such as other credit card sized devices or smartwatches, the HeartBeam technology is intended to quickly and accurately help a physician identify a heart attack (myocardial infarction). 

In the US, approximately 18 million individuals have coronary artery disease putting them at an increased risk for a heart attack and making them ideal candidates for remote patient heart attack detection. In contrast, the market for atrial fibrillation, the most targeted condition for detection by single-lead ECG technologies, is several times smaller. A 12-lead ECG is the standard of care for detecting any cardiac condition and is considered one of the essential tools for heart attack detection. No single lead ECG product currently in the marketplace is able to help diagnose a heart attack. HeartBeam’s technology will be the first and only 12-lead ECG solution that fits in a consumer’s wallet for use anytime, anywhere. 

“This patent provides additional intellectual property protection for our breakthrough AIMIGo technology offering 12-lead ECG capability in the form of a credit card-sized device with the same footprint as the single-lead products currently in the market today,” said HeartBeam CEO and Founder Branislav Vajdic, PhD. “Our 12-lead AIMIGo technology, which is part of our granted patent, offers the potential to bring a level of diagnostic accuracy consistent with the current 12-lead ECG standard of care. This could reduce the critical time to intervention for heart attack patients, saving lives and reducing healthcare costs by ruling out a heart attack and reducing the number of emergency room visits.” 

The newly issued patent (No. 11,445,963 B2) expands on HeartBeam’s granted and pending core patents for remote heart attack detection. The value of the recently granted 12-lead ECG patch patent is in addressing the market need for multi-week, continuous monitoring while the AIMIGo solution is always with the patient, providing a means for timely heart attack intervention. This may increase quality of life for cardiac patients by reducing the fear of chest pain and provide added peace of mind. At the core of both products is HeartBeam’s breakthrough ability to provide a patient-friendly means of obtaining a 12-lead ECG anytime, anywhere. 

“The availability of a remote 12-lead ECG transmitted to a physician while the patient is symptomatic and outside of a medical facility allows a standard of care level of diagnostic work in any setting and may potentially accelerate pre-hospital care,” said C. Michael Gibson, MD, MS, CEO of the non-profit Baim and PERFUSE research institutes at Harvard Medical School, also a leading digital influencer, and Chairman of HeartBeam's Scientific Advisory Board. “A 12-lead symptomatic signal combined with a 12-lead baseline signal would provide additional information to aid in diagnosing conditions such as myocardial infarction or more complex arrhythmias that current single-lead remote cardiac technologies cannot accurately detect.” 

For more information: www.heartbeam.com


Related Content

News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
News | Heart Failure

March 8, 2024 — The Texas Heart Institute, Georgia Institute of Technology (Georgia Tech), North Carolina State ...

Home March 08, 2024
Home
News | Heart Failure

March 5, 2024 — FIRE1 announced that it has completed patient enrollment in the U.S. Early Feasibility Study (FUTURE-HF2 ...

Home March 05, 2024
Home
News | Heart Failure

February 22, 2024 — Wake Forest University School of Medicine, the academic core of Advocate Health, is expanding ...

Home February 22, 2024
Home
Subscribe Now